Viomycin
Also known as: Florimycin, Tuberactinomycin B, Vio, Viocin, Viomycin sulfate
Source Viomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Viomycin is a cyclic peptide antibiotic used primarily for multidrug‑resistant Mycobacterium tuberculosis infections; its use is limited by ototoxicity and nephrotoxicity.
Mechanism of Action
Inhibits bacterial protein synthesis by binding to ribosomal RNA and causing misreading of mRNA, preventing formation of initiation complex
Routes of Administration
Goals & Uses
- Ribosome function researchResearch ToolHigh
- Multidrug‑resistant tuberculosis treatmentInfectious DiseaseModerate
- HIV reverse transcriptase inhibitionAntiviral ResearchLow
- Treatment of multidrug-resistant tuberculosisAntimicrobialModerate
Contraindications
- Pre‑existing hearing lossAuditoryHigh
- Concurrent use of other nephrotoxic agentsDrug InteractionHigh
- Pre-existing renal impairmentOrgan FunctionHigh
- Pre-existing hearing loss or vestibular dysfunctionAuditory/VestibularHigh
- Severe renal impairmentOrganHighKidney function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
Adverse Effects
- NeurotoxicityNeurologicalUncommon
- Injection site reactionsLocalCommon
- OtotoxicityAuditory/vestibularCommon
- Electrolyte disturbancesMetabolicCommon
- Neuromuscular blockadeNeuromuscularRare
- NephrotoxicityRenalCommon
Drug Interactions
- Loop diureticsModerate
- AminoglycosidesHigh
- Neuromuscular blocking agentsModerate
- Aminoglycosides (e.g., streptomycin, kanamycin)High
- Loop diuretics (e.g., furosemide)High
Population Constraints
- Pediatric patientsAgeRelative
- ElderlyAgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
- ChildrenPediatricRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in EU
- United StatesInvestigationalNot FDA‑approved; used in clinical trials for MDR‑TB
- United KingdomUnapprovedNot licensed for clinical use
Viomycin is no longer commercially available as an approved therapeutic in major markets. It was previously used in TB treatment programs but was withdrawn from clinical use. Capreomycin, a closely related tuberactinomycin, replaced it in clinical practice.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Viomycin?
Viomycin is a cyclic peptide antibiotic used primarily for multidrug‑resistant Mycobacterium tuberculosis infections; its use is limited by ototoxicity and nephrotoxicity.
What is Viomycin used for?
Viomycin is educationally associated with: Ribosome function research, Multidrug‑resistant tuberculosis treatment, HIV reverse transcriptase inhibition, Treatment of multidrug-resistant tuberculosis. Educational only — not medical advice.
How is Viomycin administered?
Recorded routes of administration: Intramuscular, Intravenous.
What are the potential side effects of Viomycin?
Reported adverse effects include: Neurotoxicity, Injection site reactions, Ototoxicity, Electrolyte disturbances, Neuromuscular blockade, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Viomycin?
Recorded contraindications: Pre‑existing hearing loss, Concurrent use of other nephrotoxic agents, Pre-existing renal impairment, Pre-existing hearing loss or vestibular dysfunction, Severe renal impairment, Pregnancy. Consult a qualified clinician before use.